Results 111 to 120 of about 50,711 (215)

Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives

open access: yesJournal of Blood Medicine, 2019
Autoimmune hemolytic anemia (AIHA) is increasingly observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reported incidence between 4% and 6%.
W. Barcellini, B. Fattizzo, A. Zaninoni
semanticscholar   +1 more source

New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia.

open access: yesTransfusion Medicine Reviews, 2022
B. Fattizzo, W. Barcellini
semanticscholar   +1 more source

Misdiagnoses of Hair and Scalp Disorders in Adult Patients With Skin of Color

open access: yes
International Journal of Dermatology, EarlyView.
Eric McMullen   +10 more
wiley   +1 more source

False-positive fourth-generation HIV test associated with autoimmune hemolytic anemia. Case report

open access: yesCase Reports, 2019
Introduction: The fourth-generation ELISA human immunodeficiency virus (HIV) screening test has a high sensitivity and specificity >99% to detect both antigens and antibodies. Estimates are that only 0.5% yield false positive results. Case description:
Santiago Sánchez-Pardo   +4 more
doaj   +1 more source

Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.

open access: yesBlood Advances, 2018
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication.
C. Schuetz   +9 more
semanticscholar   +1 more source

Neonatal Epidermolytic Ichthyosis Caused by a KRT10 Mutation (c.467G>A, p.Arg156His): A Case Report

open access: yesClinical Case Reports, Volume 13, Issue 8, August 2025.
ABSTRACT We present a neonatal case of skin blisters and erythema. While epidermolysis bullosa was initially suspected, immunofluorescence antigen mapping and genetic testing confirmed epidermolytic ichthyosis, with a heterozygous pathogenic variant in the KRT10 gene (c.467G>A, p.Arg156His).
Elke Smits   +4 more
wiley   +1 more source

Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure‐Response Analyses

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 449-458, August 2025.
Riliprubart is a second‐generation, humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway. The clinical studies of riliprubart conducted thus far for the treatment of cold agglutinin disease (CAD), a rare autoimmune disease, include a Phase 1 first‐in‐human study in healthy ...
Timothy Chow   +3 more
wiley   +1 more source

Hematologic disorders in systemic lupus erythematosus

open access: yesActa Médica del Centro, 2010
A total of 194 cases of patients suffering from systemic lupus erythematosus were reviewed. The hematologic disorders that appeared in the classification criteria were: autoimmune hemolytic anemia (Coombs-positive) in 14 patients (7%), leukopenia in 38 ...
José Francisco Martínez Delgado   +2 more
doaj  

Coexistent sickle cell anemia and autoimmune hemolytic anemia in two adolescents [PDF]

open access: yesEinstein (São Paulo)
The development of alloantibodies or autoantibodies is a complication observed in sickle cell disease. Autoimmunization occurs in 7.6-12% of chronically or intermittently transfused patients with sickle cell disease; however, the clinical implications of
Vinícius Reis Soares   +3 more
doaj   +1 more source

Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer

open access: yesInternal medicine, 2019
We herein report a 78-year old man with squamous cell carcinoma of the lungs treated with pembrolizumab. At 10 days after the administration of pembrolizumab, he showed progressive anemia and increased levels of bilirubin.
S. Okawa   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy